Sphera Funds Management LTD. Reduces Stock Holdings in Sanofi (NASDAQ:SNY)

Sphera Funds Management LTD. reduced its position in shares of Sanofi (NASDAQ:SNY) by 8.9% during the third quarter, Holdings Channel reports. The firm owned 409,515 shares of the company’s stock after selling 40,000 shares during the period. Sanofi makes up 3.8% of Sphera Funds Management LTD.’s holdings, making the stock its 2nd largest holding. Sphera Funds Management LTD.’s holdings in Sanofi were worth $23,600,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors also recently made changes to their positions in the company. State Street Corp raised its position in Sanofi by 0.5% in the third quarter. State Street Corp now owns 56,734 shares of the company’s stock worth $3,270,000 after acquiring an additional 264 shares during the period. Stifel Financial Corp raised its position in Sanofi by 2.0% in the third quarter. Stifel Financial Corp now owns 562,547 shares of the company’s stock worth $32,420,000 after acquiring an additional 10,892 shares during the period. Quantinno Capital Management LP raised its position in Sanofi by 15.8% in the third quarter. Quantinno Capital Management LP now owns 98,876 shares of the company’s stock worth $5,698,000 after acquiring an additional 13,499 shares during the period. Redwood Grove Capital LLC raised its position in Sanofi by 29.2% in the third quarter. Redwood Grove Capital LLC now owns 356,441 shares of the company’s stock worth $20,542,000 after acquiring an additional 80,537 shares during the period. Finally, Polar Asset Management Partners Inc. bought a new stake in Sanofi in the third quarter worth about $3,198,000. 10.04% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on SNY shares. Citigroup raised shares of Sanofi to a “strong-buy” rating in a research report on Tuesday, September 17th. StockNews.com lowered shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research report on Thursday, November 7th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and an average price target of $57.50.

Sanofi Stock Performance

NASDAQ SNY opened at $48.01 on Thursday. The company’s 50 day moving average is $52.42 and its 200-day moving average is $52.14. Sanofi has a 12-month low of $45.22 and a 12-month high of $58.97. The company has a quick ratio of 0.65, a current ratio of 1.00 and a debt-to-equity ratio of 0.17. The firm has a market cap of $121.84 billion, a P/E ratio of 24.49, a price-to-earnings-growth ratio of 1.22 and a beta of 0.58.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Friday, October 25th. The company reported $1.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.22 by $1.35. Sanofi had a net margin of 9.96% and a return on equity of 27.45%. The company had revenue of $13.44 billion for the quarter, compared to analyst estimates of $16.59 billion. During the same quarter in the previous year, the firm posted $2.55 earnings per share. The company’s quarterly revenue was up 12.3% compared to the same quarter last year. Sell-side analysts predict that Sanofi will post 4.28 earnings per share for the current year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.